JP Morgan Chase’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-503
Closed -$375 – 7856
2024
Q4
$375 Hold
503
– – ﹤0.01% 6834
2024
Q3
$614 Sell
503
-1
-0.2% -$2 ﹤0.01% 6781
2024
Q2
$1.04K Sell
504
-9,594
-95% -$22.6K ﹤0.01% 6610
2024
Q1
$36.9K Sell
10,098
-5,699
-36% -$21.9K ﹤0.01% 6044
2023
Q4
$47.5K Sell
15,797
-10,305
-39% -$20.9K ﹤0.01% 6015
2023
Q3
$56.1K Buy
26,102
+4,779
+22% +$19.1K ﹤0.01% 5759
2023
Q2
$119K Buy
21,323
+19,639
+1,166% +$154K ﹤0.01% 5382
2023
Q1
$10K Buy
1,684
+128
+8% +$891 ﹤0.01% 6123
2022
Q4
$9K Sell
1,556
-1,224
-44% -$6.87K ﹤0.01% 6063
2022
Q3
$15K Buy
2,780
+877
+46% +$4.44K ﹤0.01% 5884
2022
Q2
$7K Sell
1,903
-16,327
-90% -$60.8K ﹤0.01% 6108
2022
Q1
$113K Buy
18,230
+9,243
+103% +$94.4K ﹤0.01% 5452
2021
Q4
$102K Buy
8,987
+6,155
+217% +$117K ﹤0.01% 5671
2021
Q3
$53K Buy
+2,832
New +$54.3K ﹤0.01% 5826

Other funds holding OMGA

JP Morgan Chase's OMGA Position: Q1 2025 in Review

JP Morgan Chase sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q1 2025, closing a stake of 503 shares — an estimated $375 sold.

JP Morgan Chase first reported a position in OMGA in Q3 2021 and held it in 14 quarters. The position peaked at $119K in Q2 2023. 4 funds tracked by Wall St. Rank hold OMGA as of Q1 2025.

  • JP Morgan Chase reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • JP Morgan Chase sold 503 Omega Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $375.
  • JP Morgan Chase first reported a position in Omega Therapeutics, Inc. Common Stock in Q3 2021 and held it in 14 quarters.
  • JP Morgan Chase's Omega Therapeutics, Inc. Common Stock position peaked at $119K in Q2 2023.
  • 4 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.